Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pre Market Stock News Brief
Dec 01, 2008 10:05 AM
- Poniard Pharmaceuticals– Platinum Rediscovered (Part I)
May 29, 2008 12:54 PM
- Hump Day Catalysts
May 07, 2008 11:44 AM
- Par Pharma Upgrades Interest In Migraine Injection To 95%
May 07, 2008 06:57 AM
- Par Pharma Upgrades Interest In Migraine Injection To 95%
May 07, 2008 06:57 AM
- More Fed Speculation
Mar 10, 2008 09:30 AM
- STREET MOVES: Two Friedman Billings Analysts Leave Firm
Feb 08, 2008 10:47 AM
- Pre-Market - Thursday August 9th
Aug 09, 2007 12:04 PM
- UPDATE: Health-care Fund Manager Is Bullish On Fast-growing Biotechs
Aug 05, 2007 10:04 PM
- UPDATE: Health-care Fund Manager Is Bullish On Fast-growing Biotechs
Aug 05, 2007 10:04 PM
- Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy
Dec 01, 2008 07:09 AM
- Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009
Dec 01, 2008 07:06 AM
- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Nov 26, 2008 10:02 AM
- Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review
Nov 07, 2008 10:02 AM
- FUSILEV(TM) Receives Unique, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)
Nov 07, 2008 09:03 AM
- Spectrum Pharmaceuticals Announces Receipt of $41.5 Million from Allergan, Inc. Per Collaboration Agreement for Apaziquone Announced on October 29th
Nov 06, 2008 04:05 PM
- Spectrum Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Investment Conference
Nov 05, 2008 07:03 AM
- Spectrum Pharmaceuticals Announces Third Quarter 2008 Corporate Update and Pipeline Review Conference Call
Nov 04, 2008 07:06 AM
- Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
Nov 03, 2008 12:12 PM
- Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Oct 31, 2008 07:03 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
SPPI
|
Compare to S&P
|
| YTD |
-50.00 %
|
-0.01 %
|
| 4 Weeks |
-24.86 %
|
-11.05 %
|
| 12 Weeks |
-16.56 %
|
29.60 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -182.35 %
|
|
EPS Growth in Last Year: -16.67 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: 412.80 %
|
|
|
